Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

In contrast to the advances in therapy for systolic HF over the past three decades, which have improved mortality rates, no therapies have been proven to reduce mortality in patients with HFNEF (Table ...

Patients with symptomatic heart failure (HF) and normal to near-normal ejection fraction (EF) have different pathophysiological alterations compared with those with HF and low EF, and current ...

Heart failure with preserved ejection fraction (HFpEF) has limited treatment options and remains a medical challenge. HFpEF is characterized by diastolic dysfunction with a normal ejection fraction.

Background and objectives Implantable cardioverter defibrillator (ICD) therapy is indicated following a myocardial infarction ...

If you’ve been diagnosed with heart failure, your doctor has likely ordered a test of your heart's ejection fraction (EF). The EF is a measure of how efficiently your heart is pumping blood out to the ...

Heart failure with reduced ejection fraction (HFrEF) describes a type of heart failure in which the heart loses its ability to contract typically. Because of this, the heart cannot pump with enough ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

Population-based studies report that the majority of elderly patients with heart failure have a normal ejection fraction (HF-NEF) and a history of hypertension. Left ventricular diastolic dysfunction, ...

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...